Go to the list of all blogs
Vitalii Liubimov's Avatar
published in Blogs
Aug 08, 2023

$MRNA, $GMAB, $BNTX, $BGNE, $LEGN, $ALNY all dropped by over 10% in the past week.

Stocks in the biotechnology group experienced a more pronounced decline last week, with an average drop of around 10%. Our recommendations were to sell or initiate short positions. You can check signals for these stocks in the following bot: Swing-Trader-High-Volatility-Stocks-for-Active-Trading-TA-FA

Group Biotechnology Highlights: Market Cap The average market capitalization across the group is $25.3 billion. Market caps for tickers in the group range from $13 billion to $41.2 billion. MRNA holds the highest valuation in this group at $41.2 billion, while the lowest valued company is LEGN at $13 billion.

High and Low Price Notable News The average weekly price growth across all stocks in the group was -9.69%. For the same group, the average monthly price growth was -4.47%, and the average quarterly price growth was -11.7%. ALNY experienced the highest price growth at -5.69%, while MRNA experienced the largest decline at -13.99%.

  • 7/28/23 4:21 PM: Moderna (MRNA, $118.51) was a top loser this week, declining by -5.02%.
  • 6/14/23 8:29 AM: BioNTech SE American Depositary Share (BNTX, $115.6) was a top weekly gainer, with a +5.23% increase.
  • 5/25/23 7:44 AM: Legend Biotech (LEGN, $66.04) was a top loser this week, declining by -7.44%.

Volume The average weekly volume growth across all stocks in the group was 3.83%. For the same stocks in the group, the average monthly volume growth was 9.48%, and the average quarterly volume growth was 2.28%.

Fundamental Analysis Ratings The average fundamental analysis ratings, with 1 being the best and 100 being the worst, are as follows:

  • Valuation Rating: 64
  • P/E Growth Rating: 73
  • Price Growth Rating: 64
  • SMR Rating: 68
  • Profit Risk Rating: 72
  • Seasonality Score: 2 (-100 ... +100)

Notable Companies The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), and Nektar Therapeutics (NASDAQ:NKTR).

Industry Description Biotechnology involves genetic or protein engineering to produce medicines and therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry heavily focuses on research and development, striving to come up with cutting-edge solutions for health. Opportunities for growth arise from new discoveries for disease treatment. However, these discoveries must obtain regulatory approval from the U.S. Food and Drug Administration (FDA) before reaching the markets. Companies like Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation exemplify the industry.

Industry Market Cap The average market capitalization across the Biotechnology Industry is $2.1 billion. Market caps for tickers in the industry range from $402 million to $361.8 billion. NONOF holds the highest valuation in this group at $361.8 billion, while the lowest valued company is PNEXF at $402 million.

Industry High and Low Price Notable News The average weekly price growth across all stocks in the Biotechnology Industry was -4.22%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was 10.93%. VTGN experienced the highest price growth at 617.03%, while ARAV experienced the largest decline at -82.26%.

  • 7/28/23 4:21 PM: Moderna (MRNA, $118.51) was a top loser this week, declining by -5.02%.
  • 6/14/23 8:29 AM: BioNTech SE American Depositary Share (BNTX, $115.6) was a top weekly gainer, with a +5.23% increase.
  • 5/25/23 7:44 AM: Legend Biotech (LEGN, $66.04) was a top loser this week, declining by -7.44%.

Volume in the Industry The average weekly volume growth across all stocks in the Biotechnology Industry was -3.14%. For the same stocks in the industry, the average monthly volume growth was -24.5%, and the average quarterly volume growth was -0.24%.

Fundamental Analysis Ratings for the Industry The average fundamental analysis ratings, with 1 being the best and 100 being the worst, are as follows:

  • Valuation Rating: 50
  • P/E Growth Rating: 87
  • Price Growth Rating: 65
  • SMR Rating: 93
  • Profit Risk Rating: 95
  • Seasonality Score: 0 (-100 ... +100)

MRNA's Stochastic Oscillator has remained in the oversold zone for 7 days. The extended duration in the oversold zone suggests that the price of this ticker is likely to rebound soon, as an extended stay in the oversold zone often signals a more imminent uptrend.

Stock Forecast, Price, News, Quote: The current price of $101.20 has crossed the resistance line at $175.56 and is currently trading between the $175.56 resistance and the $69.57 support lines. Over the period of 07/05/23 - 08/04/23, the price experienced a -12% downtrend. During the week of 07/28/23 - 08/04/23, the stock fell by -9%.

Aroon Indicator for GMAB shows a potential upward move: GMAB's Aroon Indicator signaled a bullish trend on August 04, 2023. Tickeron's A.I. advisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the AroonUp indicator rises above 70 and the AroonDown indicator remains below 30, it suggests that the stock could be primed for a bullish move. Traders might consider buying the stock or exploring call options. A.I. advisor analyzed 323 similar instances where the Aroon Indicator displayed a similar pattern. In 242 out of 323 cases, the stock moved higher in the days following the signal. This indicates a 75% chance of a higher price movement.

Stock Forecast, Price, News, Quote: The current price of $37.60 has breached the resistance line at $40.41 and is currently trading between the $40.41 resistance and the $34.02 support lines. Over the period of 07/05/23 - 08/04/23, the price experienced a -3% downtrend. During the week of 07/28/23 - 08/04/23, the stock fell by -11%. BNTX is in an upward trend: its price may rebound because it broke its lower Bollinger Band on July 26, 2023. BNTX may climb back above the lower band and trend towards the middle band. Traders could consider purchasing the stock or exploring call options. In 24 out of 26 instances where BNTX's price breached its lower Bollinger Band, its price further increased in the following month. The probability of a continued upward trend stands at 90%.

Stock Forecast, Price, News, Quote: The current price of $98.50 has surpassed the resistance line at $153.18 and is currently trading between the $153.18 resistance and the $81.33 support lines. Over the period of 07/05/23 - 08/04/23, the price experienced a -2% downtrend. During the week of 07/28/23 - 08/04/23, the stock fell by -0.88%. BGNE's 50-day moving average has crossed bearishly below its 200-day moving average on July 17, 2023. This development could signal a long-term bearish trend for the stock as it shifts to a downward trajectory.

Stock Forecast, Price, News, Quote: The current price of $187.52 is below the lowest resistance line found by A.I. at $239.67. Over the period of 07/05/23 - 08/04/23, the price experienced a +6% uptrend, while the week of 07/28/23 - 08/04/23 reflects a -10% downtrend.

Related Ticker: MRNA, GMAB, BNTX, BGNE, LEGN, ALNY

MRNA in downward trend: 10-day moving average broke below 50-day moving average on June 28, 2024

The 10-day moving average for MRNA crossed bearishly below the 50-day moving average on June 28, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

MRNA moved below its 50-day moving average on June 26, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MRNA entered a downward trend on July 12, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 11, 2024. You may want to consider a long position or call options on MRNA as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 59%.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.632) is normal, around the industry mean (12.561). P/E Ratio (0.000) is within average values for comparable stocks, (157.093). MRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.479). Dividend Yield (0.000) settles around the average of (0.064) among similar stocks. P/S Ratio (9.107) is also within normal values, averaging (213.667).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 3B. The market cap for tickers in the group ranges from 151 to 625.55B. NONOF holds the highest valuation in this group at 625.55B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 9%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 61%. KZIA experienced the highest price growth at 347%, while HLVX experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 49%. For the same stocks of the Industry, the average monthly volume growth was 84% and the average quarterly volume growth was 49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 57
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
MRNA
 
Daily Signal changed days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of transformative medicines for patients

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Technology Square
Phone
+1 617 714-6500
Employees
5600
Web
https://www.modernatx.com
Ad is loading...
Discover the dynamic world of cryptocurrency trading with Tickeron's AI analysis. Capitalize on bullish and bearish patterns in Origin Protocol (OGN.X), with gains up to 27.80%. Stay ahead with Tickeron's real-time insights and make informed trading decisions. #CryptoTrading #AIAnalysis #OriginProtocol #InvestSmart
#latest#popular#patterns#artificial_intelligence#trading#technical_analysis
Dive into the world of trading excellence with our Best AI Robot of the week! In a market characterized by growth, the key to maximizing profits lies not only in mainstream large-cap stocks but also in exploring opportunities across different market segments.
This article delves into the performance of AI trading robots, specifically those utilizing the "Swing trader: Long-Short Equity Strategy (TA&FA)." These bots showcased their prowess by delivering a notable +4.98% gain while engaging in MRNA trades over the previous week. Beyond mere statistics, we explore the technical indicators and recent earnings report of MRNA to shed light on the underlying dynamics influencing the stock.
Artificial intelligence (AI) trading bots have become powerful tools for investors seeking active trading opportunities. In a recent analysis conducted on the "Day Trader: High Volatility Stocks for Active Trading (TA&FA)" platform, AI trading bots exhibited impressive performance, generating a noteworthy +4.81% gain while actively trading Shopify (SHOP) over the course of the previous week.
In the dynamic world of finance, strategic asset acquisition is a game-changer. Recently, a group of stocks within this domain has been in the spotlight, showcasing notable performances and intriguing patterns. This article delves into the recent movements of these stocks, focusing on key indicators, market capitalization, notable price events, and volume dynamics.
The Tickeron quant team is delighted to introduce our best robot of the week tailored for Trend Traders. Our sophisticated AI Robot, has been designed for manual trading enthusiasts who value independent signal selection.
Tickeron's Quant team is delighted to introduce our latest AI-powered robot designed for trading small-cap stocks, employing a distinctive fundamental stock analysis algorithm. This algorithm, renowned for its blend of in-depth analysis and intuitive signal-following capabilities, is well-suited for both novice and seasoned traders.
The Tickeron quant team proudly presents our top-performing AI robot for swing traders. This robot stands out with its remarkable accuracy, empowering traders to capitalize on diverse market conditions and transaction types. Demonstrating its proficiency, it achieved profitability in short trades during last week's strong uptrend in the US stock markets.
One such example is the "Trend Trader: Popular Stocks (TA&FA)" platform, where AI trading robots demonstrated their prowess by generating a notable gain while actively trading Adobe Inc. (ADBE) over the previous week. In this article, we delve into a technical analysis of ADBE's recent performance, shedding light on key indicators and recent earnings results.
​​​​​​​The railroads sector, encompassing prominent players such as Canadian Pacific Railway (CP), CSX Corporation (CSX), Norfolk Southern Corporation (NSC), Canadian National Railway Company (CNI), and Union Pacific Corporation (UNP), has undergone a noteworthy surge in performance over the past week. However, a closer examination reveals a complex landscape marked by negative outlook signals and fluctuating market dynamics.
The Tickeron quant team is excited to introduce our premier AI robot, specifically optimized for Swing Traders. This tool represents the pinnacle of our technological advancements in trading algorithms. Excelling in the market, it has achieved an impressive feat, earning twice as much as the S&P 500 in just the past week.
In the whirlwind of the current mergers and acquisitions frenzy, investors are reaping substantial rewards as stocks within the merger industry theme surged by an impressive 20.9% on average over the past month.
The Tickeron quant team is delighted to introduce our top-performing AI robot tailored for beginners. Our AI Robot specializes in navigating the high-tech stocks within the NASDAQ 100 index, renowned for their liquidity and moderate volatility—making them an ideal choice for novice traders.
In the dynamic landscape of the US stock markets, where unpredictability has become the norm, finding a trading strategy that not only thrives in periods of growth but also shields against sharp corrections is paramount.
The Tickeron quant team proudly introduces our premier AI Robot, tailor-made for trend traders who prefer manual trading and selecting their own signals. This AI Robot stands out with its impressive track record of consistent trading predictions, empowering traders to align their decisions with personal preferences.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week, given the recent downturn in major US stock indices. While the SP500, NASDAQ 100, and Dow Jones Industrial all experienced declines, our AI robot, thanks to its well-calibrated diversification across various industries, demonstrated remarkable resilience.
As the trading week came to a close on Friday, there were notable movements across various asset classes:
Tickeron's quant team diligently monitors developed trading algorithms daily to determine the most effective ones. Today, we are delighted to present three of the best robots tailored for swing traders, showcasing consistently positive results over several months, irrespective of market conditions. This week, they underscored their efficacy by yielding impressive gains across various stocks, even as major US stock indexes dipped.
Tickeron is excited to highlight the exceptional performance of our top AI robot this week. The US stock market has experienced a consistent upward trend for the past five months, heightening the anticipation of a forthcoming correction with each passing day.
Introducing our top-performing best AI Robot of the week, designed by Tickeron's expert quant team for trading small-cap stocks. This algorithm blends classical and proprietary technical indicators, honed through advanced machine learning, to empower users with effective portfolio diversification and maximum profitability in the dynamic market.